Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis
Kenji NakahamaHiroyasu KanedaKoichi OgawaYoshiya MatsumotoYoko TaniTomohiro SuzumuraShigeki MitsuokaTetsuya WatanabeKazuhisa AsaiTomoya Kawaguchi
著者情報
ジャーナル オープンアクセス

2022 年 61 巻 7 号 p. 1039-1042

詳細
抄録

A 68-year-old Japanese man was diagnosed with lung adenocarcinoma stage IVB. We introduced a first-line chemotherapy of four cycles of carboplatin and pemetrexed and pembrolizumab, followed by pemetrexed and pembrolizumab maintenance therapy. Approximately four months after anticancer therapy, a small nodule appeared in the right peripheral S3 lesion. After five months, the nodule was confirmed as a Mycobacterium tuberculosis (TB) nodule. We initiated anti-TB therapy without stopping pembrolizumab, and the right S3 nodule shrank immediately. This report supports the concurrent use of anti-TB treatment with an immune checkpoint inhibitor when the TB infection area is limited.

著者関連情報
© 2022 by The Japanese Society of Internal Medicine
前の記事 次の記事
feedback
Top